Andreas Menrad has joined Algeta ASA in Norway as chief scientific officer in order to oversee the company’s targeted cancer therapy programme. He was previously CSO at Ablynx NV and before that general manager and vice president of antibody therapeutics at Genzyme (now Sanofi SA) in Cambridge UK. Algeta develops radiopharmaceuticals and recently had a product for cancer approved by the US Food and Drug Administration. Its latest research is focused on developing targeted thorium conjugates for cancer which combine antibodies with a radionuclide. This is a different targeted approach than that being taken by other companies which are conjugating cytotoxic drugs with antibodies to produce antibody-drug conjugates.
Dr Menrad received his PhD in immunology from the University of Stuttgart in Germany and conducted post-doctoral research at the Wistar Institute Cancer Center in Philadelphia, Pennsylvania, US.
Algeta announced the appointment on 19 August 2013.
Copyright 2013 Evernow Publishing Ltd